Low-dose doxycycline prevents inflammatory bone resorption in rats

AUTOR(ES)

Bezerra, M.M., Brito, G.A.C., Ribeiro, R.A., Rocha, F.A.C.

FONTE

Brazilian Journal of Medical and Biological Research

DATA DE PUBLICAÇÃO

2002-05

RESUMO

Matrix metalloproteinases (MMP) are considered to be key initiators of collagen degradation, thus contributing to bone resorption in inflammatory diseases. We determined whether subantimicrobial doses of doxycycline (DX) (<=10 mg kg-1 day-1), a known MMP inhibitor, could inhibit bone resorption in an experimental periodontitis model. Thirty male Wistar rats (180-200 g) were subjected to placement of a nylon thread ligature around the maxillary molars and sacrificed after 7 days. Alveolar bone loss (ABL) was measured macroscopically in one hemiarcade and the contralateral hemiarcade was processed for histopathologic analysis. Groups of six animals each were treated with DX (2.5, 5 or 10 mg kg-1 day-1, sc, 7 days) and compared to nontreated (NT) rats. NT rats displayed significant ABL, severe mononuclear cell influx and increase in osteoclast numbers, which were significantly reduced by 5 or 10 mg kg-1 day-1 DX. These data show that DX inhibits inflammatory bone resorption in a manner that is independent of its antimicrobial properties.

Documentos Relacionados

• Low-dose droperidol
• Low-dose droperidol
• Low-dose bromocriptine in Parkinson's disease.
• Ocular surface changes in the treatment of rosacea: comparison between low-dose oral isotretinoin and doxycycline
• Essential fatty acid deficiency prevents multiple low-dose streptozotocin-induced diabetes in CD-1 mice.